期刊
CURRENT OPINION IN ONCOLOGY
卷 19, 期 2, 页码 116-120出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0b013e32801497c6
关键词
chemotherapy; immunotherapy; melanoma; targeted therapy
类别
Purpose of review New approaches to melanoma are emerging. This review summarizes developments over the past 12 months. Recent findings Surgical, chemotherapeutic, immunologic land targeted therapies for melanoma are evolving. Sentinel lymph node sampling is now accepted as the standard of care for patients with intermediate thickness primary melanomas. Temozolomide continues to be widely used as part of combination therapy, and recent evidence suggests that a combination of temozolomide and interferon-a may be superior to temozolomide alone. Meanwhile, temozolomide and thalidomide carries unacceptable thrombosis risk. In the area of immunotherapy, anti-CTLA-4 continues to show promise, but special attention must be paid to gastrointestinal toxicity. Interferon-alpha, in addition, has shown efficacy in the neoadjuvant setting with inflammatory infiltrates demonstrated in tumors. A better understanding of the complex genetic regulation of melanoma cell growth is emerging and this is expected to lead to the development of novel targeted therapies. Summary Research is producing a more complete understanding of melanoma genetics and immune regulation. These are beginning to produce therapeutics that are impacting clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据